GenSight Biologics S.A. (SIGHTP.XC)
| Previous close | 0.5530 |
| Open | 0.5570 |
| Bid | 0.5320 x N/A |
| Ask | 0.5430 x N/A |
| Day's range | 0.5400 - 0.5570 |
| 52-week range | 0.5400 - 3.5280 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 54.825M |
| Beta (5Y monthly) | 2.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6300 |
| Earnings date | 23 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireGenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
PARIS, June 20, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the renegotiation of certain financial obligations, securing its financial position and improving short-term flexibility. The Company also provided operational updates.
Business WireGenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
PARIS, June 04, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its participation at key medical and stakeholder meetings in the remainder of 2024.
Business WireGenSight Biologics Appoints William Monteith to its Board of Directors
PARIS, June 03, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the appointment of William Monteith to its Board of Directors. Mr. Monteith joined as an independent Director after existing Board members approved his nomination at the meeting on May 29, 2
